creation of innovative medical products and services for the benefit community human health around world yasuhiro tsuji ph d department manager product strategy dept r&d activity forward looking statements this presentation may include pertaining to business prospects chugai pharmaceutical co ltd company these reflect s current analysis existing information trends actual results differ from expectations based on risks uncertainties that affect businesses 2 sales composition focused therapeutic areas source ims 2003 jan dec jp rx market 77 618 mm in ranked no 4 share 893 1 110 jpy renal 32 1418m bone joint 11 360m cancer 25 802m infection 10 311m cardiovascular 312m others 12 375m furtulon xeloda neutrogin kytril rituxan herceptin epogin oxarol renagel alfarol rocaltrol suvenyl sigmart rythmodan preran tamiflu pegasys rocephin cefotax rohypnol amoban ulcerlmin euglucon 3 japan biopharmaceutical shares erythropoietin 66 g csf 40 antibodies 69 415 5 billion us 55 28 0 30
